Victory Capital Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Victory Capital Management’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.6M	Buy	60,937 +535	+0.9%	+$12.5K	﹤0.01%	1699
2026 Q1	$1.42M	Sell	60,402 -6,036	-9%	-$154K	﹤0.01%	1705
2025 Q4	$1.93M	Buy	66,438 +394	+0.6%	+$10.1K	﹤0.01%	1595
2025 Q3	$1.24M	Buy	66,044 +34,180	+107%	+$539K	﹤0.01%	1741
2025 Q2	$447K	Buy	31,864 +19,257	+153%	+$270K	﹤0.01%	2078
2025 Q1	$197K	Sell	12,607 -127	-1%	-$1.79K	﹤0.01%	2223
2024 Q4	$177K	Sell	12,734 -109	-0.8%	-$1.19K	﹤0.01%	2260
2024 Q3	$119K	Buy	12,843 +1,155	+10%	+$11.4K	﹤0.01%	2305
2024 Q2	$109K	Sell	11,688 -487	-4%	-$4.4K	﹤0.01%	2285
2024 Q1	$121K	Buy	12,175 +1,756	+17%	+$13.1K	﹤0.01%	2280
2023 Q4	$33.7K	Buy	+10,419	New	+$28.3K	﹤0.01%	2474
2022 Q4	–	Sell	-25,000	Closed	-$478K	–	2594
2022 Q3	$478K	Buy	+25,000	New	+$566K	﹤0.01%	2073
2020 Q2	–	Sell	-3,860	Closed	-$115K	–	2552
2020 Q1	$115K	Buy	+3,860	New	+$104K	﹤0.01%	2286

Other funds holding ARQT

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Victory Capital Management's ARQT Position: Q2 2026 in Review

Victory Capital Management increased its Arcutis Biotherapeutics (ARQT) stake by 0.89% in Q2 2026, buying an estimated $12.5K and bringing the position to 60,937 shares worth $1.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1699.

Victory Capital Management first reported a position in ARQT in Q1 2020 and has held it in 13 quarters since. The position peaked at $1.93M in Q4 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

Victory Capital Management held 60,937 shares of Arcutis Biotherapeutics worth $1.6M as of Q2 2026.
Victory Capital Management bought 535 Arcutis Biotherapeutics shares in Q2 2026, an estimated $12.5K.
Arcutis Biotherapeutics made up ﹤0.01% of Victory Capital Management's portfolio in Q2 2026, its #1699 holding.
Victory Capital Management first reported a position in Arcutis Biotherapeutics in Q1 2020 and has held it in 13 quarters since.
Victory Capital Management's Arcutis Biotherapeutics position peaked at $1.93M in Q4 2025.
272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Victory Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.